Cytogen's ProstaScint enters IMRT (intensity modulated radiation therapy) trials:
This article was originally published in Clinica
A phase I/II clinical study is underway to evaluate Cytogen's ProstaScint imaging agent in improving the precision of intensity modulated radiation therapy (IMRT) for prostate cancer. ProstaScint, a radiolabelled monoclonal antibody, is injected intravenously into the patient where it binds to a highly expressed marker for prostate cancer. The enhanced images will allow for radiation to be more highly focused on the tumour, reducing damage to the surrounding tissue, said the Princeton, New Jersey firm.
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.